November 28, 2022Open Access

Endotrophin is a risk marker of complications in CANagliflozin cardioVascular Assessment Study (CANVAS): a randomized controlled trial

DRDaniel Guldager Kring RasmussenNovo Nordisk (Denmark)MHMichael K. HansenUniversity of Michigan JBJoseph BlairUniversity of Copenhagen

Structured PICO

Does Endotrophin (P-ETP) predict cardiovascular, kidney and mortality outcomes in patients with type 2 diabetes?

Population

Patients with type 2 diabetes

Intervention

Endotrophin (P-ETP) measurement

Outcome

Cardiovascular, kidney and mortality outcomeshard clinical

Endotrophin (P-ETP) is a risk marker that predicts cardiovascular, kidney, and mortality outcomes in patients with type 2 diabetes, potentially useful for patient enrichment in future trials.

Abstract

P-ETP generated during COL VI formation predicts cardiovascular, kidney and mortality outcomes in patients with type 2 diabetes. As ETP identifies patients at increased risk of experiencing relevant outcomes, it may be used for patient enrichment in future clinical trials. Trial Registry Number (ClinicalTrials.gov Identifier): NCT01032629.

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper

Cite This Study

Rasmussen et al. (Mon,) studied this question.

synapsesocial.com/papers/69d72afccd480cb7e5f50ef0 https://doi.org/https://doi.org/10.1186/s12933-022-01666-7

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper